<p>加拿大温哥华，2026 年 1 月 14 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（纳斯达克：CMND），（法兰克福证券交易所：CWY0）（“Clearmind” 或 “公司”）是一家临床阶段的生物技术公司，专注于发现和开发新型神经可塑素衍生的治疗药物，以解决主要的未得到充分治疗的健康问题。今天，公司宣布其正在进行的 FDA 批准的 I/IIa 期临床试验的第二组所有患者的治疗已成功完成，该试验评估了 CMND-100，即公司自主研发的基于 MEAI 的口服药物候选者，用于治疗酒精使用障碍（AUD）。</p>
<p>第二组由六名患者组成，这些患者来自包括约翰霍普金斯大学、特拉维夫索拉斯基医疗中心和哈达萨医疗中心在内的顶级临床机构，现已按照协议完全完成治疗。这个里程碑建立在第一组的积极结果之上，第一组显示出良好的安全性特征和初步的疗效信号，包括减少渴求和戒断症状。</p>
<p>“我们很高兴地宣布第二组的治疗成功完成，这在获得 DSMB 批准继续招募后一个月内实现，标志着我们跨国 I/IIa 期试验的持续稳定进展，” Clearmind Medicine 首席执行官 Adi Zuloff-Shani 博士表示。“这一成就反映了我们临床机构的奉献精神以及对 CMND-100 作为 AUD 潜在创新疗法的强烈兴趣，这是一种具有显著未满足医疗需求的疾病。我们期待即将发布的数据，并向后续组别推进。”</p>
<p>I/IIa 期试验是一项跨国、多中心研究，旨在评估 CMND-100 在中度至重度 AUD 患者中的安全性、耐受性、药代动力学和初步疗效。第二组的顶线结果预计将在未来几个月内公布。</p>
<p><strong>关于 Clearmind Medicine Inc.</strong></p>
<p>Clearmind 是一家临床阶段的迷幻药物生物技术公司，专注于发现和开发新型迷幻药衍生的治疗药物，以解决广泛且未得到充分服务的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
<p>公司的知识产权组合目前包括十九个专利系列，其中包括 31 项已授予的专利。公司打算在必要时为其化合物申请更多专利，并将保持机会主义，收购更多知识产权以扩展其组合。</p>
<p>Clearmind 的股票在纳斯达克以 “CMND” 符号交易，在法兰克福证券交易所以 “CWY0” 符号交易。</p>
<p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
<p>投资者关系</p>
<p>invest@clearmindmedicine.com</p>
<p>电话：（604）260-1566</p>
<p>美国：CMND@crescendo-ir.com</p>
<p>一般咨询</p>
<p>Info@Clearmindmedicine.com</p>
<p>www.Clearmindmedicine.com</p>
<p><strong>前瞻性声明：</strong></p>
<p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法意义上的 “前瞻性声明”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语或类似表达或变体旨在识别前瞻性声明。例如，公司在讨论我们跨国 I/IIa 期试验的进展、对 CMND-100 作为 AUD 潜在创新疗法的兴趣以及向后续组别推进时使用了前瞻性声明。前瞻性声明不是历史事实，基于管理层当前的期望、信念和预测，许多预测本质上是不确定的。这些期望、信念和预测是以诚信表达的。然而，无法保证管理层的期望、信念和预测将会实现，实际结果可能与前瞻性声明中所表达或暗示的结果有重大差异。前瞻性声明受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中所表达的有重大差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2024 年 10 月 31 日的财政年度的 20-F 表格年报中详细列出的风险。前瞻性声明仅在声明发布之日有效。公司不承担更新前瞻性声明以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性声明，不应推断公司将就此或其他前瞻性声明进行额外更新。提供的参考和链接到网站仅为方便，网站上包含的信息不被纳入本新闻稿的引用。Clearmind 对第三方网站的内容不承担责任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UVTRPQ00zTXpZeE1ESTBJelV3TURBNE5qa3pOQT09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UVTRPQ00zTXpZeE1ESTBJelV3TURBNE5qa3pOQT09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzhkYWVjNjEtOWU4OS00ZGRhLTgyNTAtYjIzOWQzZjNkMjMyLTUwMDA4NjkzNC0yMDI2LTAxLTE0LWVu/tiny/Clearmind-Medicine-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzhkYWVjNjEtOWU4OS00ZGRhLTgyNTAtYjIzOWQzZjNkMjMyLTUwMDA4NjkzNC0yMDI2LTAxLTE0LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

CMND

<p>Clearmind Medicine Inc. 已成功完成其 CMND-100（用于治疗酒精使用障碍（AUD）的药物候选者）第一/二期临床试验第二组所有患者的治疗。该试验包括来自知名临床机构的六名患者，继第一组的积极结果之后进行。首席执行官 Dr. Adi Zuloff-Shani 对进展表示满意，并强调了 CMND-100 作为 AUD 创新疗法的潜力。该组的初步结果预计很快会公布</p>

<p>Vancouver, Canada, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the &#34;Company&#34;), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD).</p>
<div class="lb-trans"><p>加拿大温哥华，2026 年 1 月 14 日（GLOBE NEWSWIRE）——Clearmind Medicine Inc.（纳斯达克：CMND），（法兰克福证券交易所：CWY0）（“Clearmind” 或 “公司”）是一家临床阶段的生物技术公司，专注于发现和开发新型神经可塑素衍生的治疗药物，以解决主要的未得到充分治疗的健康问题。今天，公司宣布其正在进行的 FDA 批准的 I/IIa 期临床试验的第二组所有患者的治疗已成功完成，该试验评估了 CMND-100，即公司自主研发的基于 MEAI 的口服药物候选者，用于治疗酒精使用障碍（AUD）。</p>
</div><p>The second cohort, consisting of six patients recruited across premier clinical sites, including Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, has now fully completed the treatment per protocol. This milestone builds on the positive results from the first cohort, which demonstrated a favorable safety profile and preliminary efficacy signals, including reduced cravings and withdrawal symptoms.</p>
<div class="lb-trans"><p>第二组由六名患者组成，这些患者来自包括约翰霍普金斯大学、特拉维夫索拉斯基医疗中心和哈达萨医疗中心在内的顶级临床机构，现已按照协议完全完成治疗。这个里程碑建立在第一组的积极结果之上，第一组显示出良好的安全性特征和初步的疗效信号，包括减少渴求和戒断症状。</p>
</div><p>“We are pleased to announce the successful completion of treatment in the second cohort, within a month after receiving DSMB approval to continue enrollment, marking continued steady progress in our multinational Phase I/IIa trial,” said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. “This achievement reflects the dedication of our clinical sites and the strong interest in CMND-100 as a potential innovative therapy for AUD, a condition with significant unmet medical needs. We look forward to upcoming data readouts and advancing toward subsequent cohorts.”</p>
<div class="lb-trans"><p>“我们很高兴地宣布第二组的治疗成功完成，这在获得 DSMB 批准继续招募后一个月内实现，标志着我们跨国 I/IIa 期试验的持续稳定进展，” Clearmind Medicine 首席执行官 Adi Zuloff-Shani 博士表示。“这一成就反映了我们临床机构的奉献精神以及对 CMND-100 作为 AUD 潜在创新疗法的强烈兴趣，这是一种具有显著未满足医疗需求的疾病。我们期待即将发布的数据，并向后续组别推进。”</p>
</div><p>The Phase I/IIa trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Topline results from the second cohort are anticipated in the coming months.</p>
<div class="lb-trans"><p>I/IIa 期试验是一项跨国、多中心研究，旨在评估 CMND-100 在中度至重度 AUD 患者中的安全性、耐受性、药代动力学和初步疗效。第二组的顶线结果预计将在未来几个月内公布。</p>
</div><p><strong>About Clearmind Medicine Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Clearmind Medicine Inc.</strong></p>
</div><p>Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.</p>
<div class="lb-trans"><p>Clearmind 是一家临床阶段的迷幻药物生物技术公司，专注于发现和开发新型迷幻药衍生的治疗药物，以解决广泛且未得到充分服务的健康问题，包括酒精使用障碍。其主要目标是研究和开发基于迷幻药的化合物，并尝试将其商业化为受监管的药物、食品或补充剂。</p>
</div><p>The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.</p>
<div class="lb-trans"><p>公司的知识产权组合目前包括十九个专利系列，其中包括 31 项已授予的专利。公司打算在必要时为其化合物申请更多专利，并将保持机会主义，收购更多知识产权以扩展其组合。</p>
</div><p>Shares of Clearmind are listed for trading on Nasdaq under the symbol &#34;CMND&#34; and the Frankfurt Stock Exchange under the symbol “CWY0.”</p>
<div class="lb-trans"><p>Clearmind 的股票在纳斯达克以 “CMND” 符号交易，在法兰克福证券交易所以 “CWY0” 符号交易。</p>
</div><p>For further information, visit: https://www.clearmindmedicine.com or contact:</p>
<div class="lb-trans"><p>欲了解更多信息，请访问：https://www.clearmindmedicine.com 或联系：</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>invest@clearmindmedicine.com</p>
<div class="lb-trans"><p>invest@clearmindmedicine.com</p>
</div><p>Telephone: (604) 260-1566</p>
<div class="lb-trans"><p>电话：（604）260-1566</p>
</div><p>US: CMND@crescendo-ir.com</p>
<div class="lb-trans"><p>美国：CMND@crescendo-ir.com</p>
</div><p>General Inquiries</p>
<div class="lb-trans"><p>一般咨询</p>
</div><p>Info@Clearmindmedicine.com</p>
<div class="lb-trans"><p>Info@Clearmindmedicine.com</p>
</div><p>www.Clearmindmedicine.com</p>
<div class="lb-trans"><p>www.Clearmindmedicine.com</p>
</div><p><strong>Forward-Looking Statements:</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明：</strong></p>
</div><p>This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses progress in our multinational Phase I/IIa trial, interest in CMND-100 as a potential innovative therapy for AUD and advancing toward subsequent cohorts. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.</p>
<div class="lb-trans"><p>本新闻稿包含《私人证券诉讼改革法案》和其他证券法意义上的 “前瞻性声明”。诸如 “预计”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计” 等词语或类似表达或变体旨在识别前瞻性声明。例如，公司在讨论我们跨国 I/IIa 期试验的进展、对 CMND-100 作为 AUD 潜在创新疗法的兴趣以及向后续组别推进时使用了前瞻性声明。前瞻性声明不是历史事实，基于管理层当前的期望、信念和预测，许多预测本质上是不确定的。这些期望、信念和预测是以诚信表达的。然而，无法保证管理层的期望、信念和预测将会实现，实际结果可能与前瞻性声明中所表达或暗示的结果有重大差异。前瞻性声明受到风险和不确定性的影响，这可能导致实际表现或结果与前瞻性声明中所表达的有重大差异。有关影响公司的风险和不确定性的更详细描述，请参考公司不时向证券交易委员会（“SEC”）提交的报告，包括但不限于公司截至 2024 年 10 月 31 日的财政年度的 20-F 表格年报中详细列出的风险。前瞻性声明仅在声明发布之日有效。公司不承担更新前瞻性声明以反映实际结果、后续事件或情况、假设变化或影响前瞻性信息的其他因素的义务，除非适用的证券法要求。如果公司更新一项或多项前瞻性声明，不应推断公司将就此或其他前瞻性声明进行额外更新。提供的参考和链接到网站仅为方便，网站上包含的信息不被纳入本新闻稿的引用。Clearmind 对第三方网站的内容不承担责任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UVTRPQ00zTXpZeE1ESTBJelV3TURBNE5qa3pOQT09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyNTU4OCM3MzYxMDI0IzUwMDA4NjkzNA=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/MzhkYWVjNjEtOWU4OS00ZGRhLTgyNTAtYjIzOWQzZjNkMjMyLTUwMDA4NjkzNC0yMDI2LTAxLTE0LWVu/tiny/Clearmind-Medicine-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/MzhkYWVjNjEtOWU4OS00ZGRhLTgyNTAtYjIzOWQzZjNkMjMyLTUwMDA4NjkzNC0yMDI2LTAxLTE0LWVu/tiny/Clearmind-Medicine-Inc-.png"/></p>

Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 | CMND Stock News

Clearmind Medicine 宣布成功完成正在进行的 CMND-100 I/IIa 期临床试验中第二组所有患者的治疗 | CMND 股票新闻